Country: South Korea

Oncocross is an AI-driven precision medicine company focused on transcriptome-based drug indication discovery and patient stratification. Through in-depth analysis of gene expression patterns and their links to disease biology, the company enables pharmaceutical and clinical partners to identify optimal therapeutic indications, uncover mechanism-of-action-aligned opportunities, and define responsive patient subpopulations. Its proprietary RAPTOR AI platform compares transcriptomic signatures across diseases, drug perturbations, and clinical states, forming the foundation for ONCO-RAPTOR AI in oncology and ONCOfind AI, a blood-based metabolomics solution for non-invasive cancer screening. Together, these platforms reflect Oncocross’ strategy to build a scalable multi-omics intelligence ecosystem that advances both drug development and clinical precision. To further strengthen its capabilities beyond transcriptomics, Oncocross has strategically expanded into proteomics through NeoOmics, a proteome and targeted protein degradation (TPD)-focused platform. Following strategic investment and infrastructure development, the company has established an end-to-end proteomics system that is fully automated from sample preparation to analysis. This enables high-throughput, low-bias, and highly reproducible protein profiling across a wide range of sample types, including cells, blood, and tissue specimens. NeoOmics is already supporting pharmaceutical companies and medical institutions by generating high-quality proteomics evidence for drug development and clinical translation, and is particularly well positioned to address key challenges in emerging modalities such as TPD—ranging from off-target toxicity prediction to ternary complex efficiency assessment. As the company continues to scale, Oncocross is entering a new phase in which its AI platforms are increasingly applied not only to preclinical discovery but also to clinical-stage decision support. The company is actively strengthening its clinical evidence base through collaborations with major hospitals and research networks, securing high-quality prospective and retrospective clinical datasets and biospecimens. By integrating real-world clinical data (RWD) with its proprietary algorithms, Oncocross continues to improve predictive accuracy while deepening mechanistic interpretability—bridging computational insights with real clinical outcomes. Looking ahead, Oncocross is pursuing a clear strategic direction: evolving from single-omics analysis into a fully integrated multi-omics platform spanning transcriptomics, proteomics, and metabolomics. The company’s long-term vision is to build a “Virtual Cell” capability—an advanced framework designed to simulate drug-induced biological responses in a digital environment, enabling more accurate prediction of efficacy, safety, and patient response prior to clinical testing. Through continuous expansion of its data infrastructure, further automation of experimental workflows, and deeper integration with clinical networks, Oncocross aims to become a global leader in multi-omics data intelligence and a key enabler of mechanism-based precision medicine.